The PERTINENT study measured biomarkers of atherosclerosis and thrombosis in a stable coronary artery disease population from EUROPA receiving ACE inhibition with perindopril 8 mg/day or placebo. Biomarkers of inflammation, C-reactive protein (CRP), fibrinogen, and tumor necrosis factor-alpha (TNF-α), and a biomarker of thrombosis, d-dimer, were measured at baseline and 1 year. CRP was recorded in 1157 patients; fibrinogen, TNF-α, and d-dimer in 291 patients. There was no significant effect of treatment on CRP or fibrinogen. In contrast, there were significant reductions in TNF-α (27.60-25.20 pg/mL; P < 0.05) and d-dimer (0.24-0.18 μg/mL; P < 0.05) with perindopril over 1 year. Survival analysis of the prognostic significance of baseline CRP failed to detect a significant role for the prediction of cardiovascular events over 4 years (lower versus higher tertile: 1.54; 95% confidence interval 0.88-2.68; P = 0.16). In conclusion, in the PERTINENT trial, we observed significant effects of ACE inhibition on biomarkers of the atherothrombotic complications (d-dimer) and the proinflammatory cytokine TNF-α, but not on biomarkers of inflammation associated with atherosclerosis (CRP and fibrinogen).

Additional Metadata
Keywords ACE inhibition, Coronary artery disease, Inflammation, Perindopril, Thrombosis
Persistent URL,
Journal Atherosclerosis
Ceconi, C, Fox, K.M, Remme, W.J, Simoons, M.L, Deckers, J.W, Bertrand, M.E, … Ferrari, R. (2008). ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study. Atherosclerosis, 204(1), 273–275. doi:10.1016/j.atherosclerosis.2008.08.042